| |
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
Today’s Big NewsAug 12, 2024 |
| By Fraiser Kansteiner On Friday, the FDA declined to approve Lykos’ midomafetamine (MDMA) therapy in patients with PTSD. Lykos had been seeking approval of its MDMA capsule along with psychological intervention, also known as MDMA-assisted therapy. |
|
|
|
By Nick Paul Taylor Avidity Biosciences impressed investors with phase 1/2 data in Duchenne muscular dystrophy Friday, extending its winning streak in the clinic. But closer examinations of the data revealed details that analysts said present a much more nuanced picture than what the headline result implies. |
By James Waldron The initial stages of oncology R&D aren’t short of intriguing new modalities, and Halda Therapeutics is planning to join them by using $126 million in fresh funding to run its RIPTAC program into the clinic. |
By James Waldron Antibody-drug conjugates have been at the center of many a billion-dollar biobuck licensing deal over the last year, but Bivictrix Therapeutics feels like it’s been missing out. |
By James Waldron Actinogen Medical’s cortisol blocker has failed to hit the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease. |
By Heather Landi Nearly a year after it announced a collaboration with Microsoft, digital pathology player Paige unveiled the second generation of an image-based AI model to help detect cancer. |
By Fraiser Kansteiner Following last year’s acquisition of viral vector and plasmid specialist Forge Biologics, Japan’s Ajinomoto Bio-Pharma Services is streamlining its business in San Diego. As a result, 71 California-based staffers—or 13% of the company’s overall workforce—are set to lose their jobs, Ajinomoto said in a memo shared with Fierce Pharma. |
By Noah Tong The donor class is not happy with Lina Khan's interpretation of antitrust enforcement at the FTC, and they want her gone. Here's how likely that is to happen and how it could impact pharmacy benefit managers under a new administration. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
